Testosterone Cypionate vs Enclomiphene Citrate: Switching Between Them

What Each Drug Actually Does

Testosterone cypionate is an esterified form of testosterone injected intramuscularly or subcutaneously. Once cleaved by plasma esterases, it behaves identically to endogenous testosterone. Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus, prompting the pituitary to release more LH and FSH.

Testosterone Cypionate: Exogenous Replacement

The FDA has approved testosterone cypionate (Depo-Testosterone) for hypogonadism since 1979. Prescribing information on the FDA label lists standard dosing at 50 to 400 mg every 2 to 4 weeks, though most modern TRT protocols use 100 to 200 mg per week or biweekly to avoid supraphysiologic peaks. Because the drug delivers testosterone directly, results appear quickly. Most patients see measurable serum T increases within 48 to 72 hours of the first injection.

The tradeoff is HPG axis suppression. Exogenous testosterone signals the hypothalamus and pituitary to cut LH and FSH output. Testicular testosterone production falls, often to near zero, and sperm counts drop substantially within 6 to 12 weeks of starting therapy. The American Urological Association's 2022 testosterone deficiency guideline explicitly warns that patients who want to preserve fertility should avoid exogenous testosterone monotherapy.

Enclomiphene Citrate: Endogenous Stimulation

Enclomiphene blocks hypothalamic estrogen receptors, reducing negative feedback. LH and FSH rise. The testes then produce more testosterone and, critically, continue making sperm. In Kim et al. (BJU Int 2016, N=71), enclomiphene citrate restored mean serum testosterone from 230 ng/dL to 412 ng/dL while keeping semen parameters stable or improved across a 3-month treatment period. PubMed link to Kim 2016.

Because enclomiphene is oral and daily, there are no injection-site reactions and no weekly clinic visits. The steady-state pharmacokinetics also avoid the testosterone peaks and troughs associated with weekly cypionate injections, which some men find causes mood fluctuation in the days before the next dose.

How Effective Is Each Agent at Raising Testosterone?

Both drugs can reliably move serum testosterone into the normal male range (300 to 1,000 ng/dL per Endocrine Society 2018 guidelines), but the degree of response differs by mechanism and by the patient's own HPG axis reserve.

Cypionate Efficacy Data

The T-Trials consortium (NEJM 2016, N=788 men aged 65 or older with serum T <275 ng/dL) randomized participants to testosterone gel 1% or placebo for 12 months. Published in NEJM, the sexual-function trial showed a statistically significant improvement on the Psychosexual Daily Questionnaire (P<0.001) and increased walking distance of 34.2 meters vs placebo (P<0.001). The T-Trials used gel, not cypionate, but the pharmacodynamic endpoints transfer because both deliver the same active hormone. Cypionate injections produce higher peak testosterone levels than gel, making them the standard for men who need strong symptom control quickly.

Enclomiphene Efficacy Data

A randomized, double-blind, placebo-controlled trial published in the Journal of Urology (Wiehle et al., 2014, N=124) showed that 12.5 mg and 25 mg daily doses of enclomiphene citrate raised serum testosterone by 147 ng/dL and 219 ng/dL, respectively, at 3 months while maintaining or increasing LH and FSH. PubMed link to Wiehle 2014. A separate crossover analysis from the same group found that enclomiphene maintained testosterone in the 400 to 500 ng/dL range for 6 months without suppressing testicular volume. PubMed crossover data.

These numbers are lower than what many men achieve on 150 to 200 mg/week of testosterone cypionate, where trough values routinely reach 600 to 900 ng/dL. Men with primary hypogonadism (testicular failure) will not respond to enclomiphene at all, because the testes cannot respond to LH stimulation regardless of how high pituitary output rises.

Fertility: The Deciding Factor for Many Men

Cypionate Suppresses Sperm

Testosterone cypionate is a reliable contraceptive. The WHO male contraception studies from the 1990s showed that weekly 200 mg testosterone enanthate injections (pharmacologically equivalent to cypionate) suppressed sperm counts to <3 million/mL in 98% of men within 6 months. WHO Task Force trial on male contraception, PubMed. Recovery of sperm production after stopping TRT takes an average of 3 to 6 months but can extend to 2 years in some men. Contraception 2006 meta-analysis on TRT-induced azoospermia recovery.

Enclomiphene Preserves Sperm

Enclomiphene is the only oral option studied specifically for secondary hypogonadism that maintains spermatogenesis. Kim et al. (2016) found that total motile sperm count was preserved at baseline levels throughout treatment. PubMed Kim 2016. For men under 45 who plan to father children within 2 to 5 years, this difference is not minor. Sperm cryopreservation before starting TRT is one workaround, but it adds cost and does not guarantee future fertility if the HPG axis recovers slowly.

The Endocrine Society clinical practice guideline on male hypogonadism states: "We suggest using gonadotropins or clomiphene citrate for the treatment of hypogonadism in men who want to preserve fertility, rather than testosterone therapy." Enclomiphene, as the active isomer of clomiphene, fits directly into this recommendation.

Side Effect Profiles Compared

Cypionate-Specific Risks

Exogenous testosterone raises hematocrit. The T-Trials (NEJM 2016) found a statistically significant increase in hematocrit to above 54% in 5.9% of testosterone-treated men vs 0.4% in placebo (P<0.001). NEJM T-Trials hematology data. Elevated hematocrit raises the risk of thromboembolic events. Cypionate also aromatizes to estradiol. Without monitoring, men on 100 to 200 mg/week can develop elevated estradiol levels, causing gynecomastia or water retention. Injection-site nodules, skin irritation, and the inconvenience of self-injecting are practical concerns for some patients.

An FDA Drug Safety Communication issued in 2014 and updated since warns of cardiovascular risks associated with testosterone products. FDA testosterone safety communication. Prescribers are expected to discuss this with patients before initiating therapy.

Enclomiphene-Specific Risks

Enclomiphene's SERM mechanism can raise estradiol, though typically less than exogenous testosterone aromatization does. Visual disturbances, a known class effect of clomiphene compounds, have been reported with enclomiphene, though at lower rates than with the zuclomiphene (cis) isomer that causes most of the side effects in racemic clomifene. Mood effects, including irritability, may occur in some men. Long-term safety data beyond 12 months remain limited because no large Phase 3 trial has completed a 2-year endpoint in males. The FDA's Complete Response Letter for Androxal (enclomiphene) in 2013 and 2015 identified this data gap as a barrier to approval. This makes enclomiphene off-label in the US, meaning insurance rarely covers it and prescribers assume more clinical responsibility.

Who Is the Better Candidate for Each Drug?

The decision tree below synthesizes the clinical data above into a practical framework. This is not a set of rigid rules. It is a starting scaffold for shared clinical decision-making.

Choose testosterone cypionate if:

• Hypogonadism is primary (testicular failure; FSH already elevated)
• Patient is not planning future fertility
• Symptoms are severe and require fast, reliable testosterone normalization
• Patient has already failed a 3-month trial of clomiphene or enclomiphene
• Patient is enrolled in testosterone replacement monitoring with regular hematocrit and PSA checks

Choose enclomiphene citrate if:

• Hypogonadism is secondary (low LH/FSH confirm intact pituitary-gonadal pathway)
• Patient plans to father children within the next 3 to 5 years
• Patient prefers daily oral dosing over weekly injections
• Serum testosterone is in the 200 to 350 ng/dL range with milder symptom burden
• Patient has a contraindication to elevated hematocrit (e.g., history of polycythemia vera)

Men with total testosterone consistently <200 ng/dL and severe symptoms are unlikely to achieve adequate response with enclomiphene alone. Endocrine Society guidelines set 300 ng/dL as the treatment threshold, but men with levels <200 ng/dL typically have more severe pituitary or testicular impairment.

Switching from Testosterone Cypionate to Enclomiphene Citrate

Why Men Switch

The most common reason men want to switch from TRT to enclomiphene is a change in fertility plans. A man who started cypionate at 32 and now wants to conceive at 36 is a prototypical example. Other reasons include polycythemia that does not resolve with therapeutic phlebotomy, a desire to avoid injections long-term, or concerns about HPG axis suppression after reading updated literature.

The Recovery Window

After stopping testosterone cypionate, the HPG axis does not recover instantly. LH and FSH typically begin rising within 4 to 6 weeks, but testicular testosterone production may remain below baseline for 3 to 6 months, and sperm recovery can take up to 12 to 18 months in some men. A 2013 review in the Journal of Sexual Medicine found that HPG axis recovery after TRT discontinuation averaged 4.2 months (range: 2 to 24 months) across 55 published cases. PubMed HPG recovery after TRT.

The Switching Protocol

A practical approach used at HealthRX and consistent with Endocrine Society guidance involves:

1. Stop testosterone cypionate. Do not taper; abrupt cessation is standard.
2. Measure LH, FSH, total testosterone, and semen analysis at 4 weeks and 8 weeks.
3. Start enclomiphene citrate 12.5 mg daily once LH begins rising (or at 4 to 6 weeks if LH remains suppressed, to stimulate recovery).
4. Re-check serum testosterone at 6 to 8 weeks on enclomiphene. Titrate to 25 mg daily if T remains <350 ng/dL and symptoms persist.
5. Repeat semen analysis at 3 months to confirm spermatogenesis recovery.

Some clinicians add hCG (human chorionic gonadotropin) 500 to 1,000 IU three times per week during the bridging period to accelerate testicular recovery. PubMed data on hCG for TRT-induced hypogonadism recovery. This is an off-label use of hCG but is consistent with the pharmacology of LH-receptor stimulation.

Monitoring After the Switch

Labs to check at weeks 4, 8, and 12 post-switch: total testosterone, free testosterone, LH, FSH, estradiol, CBC (hematocrit should begin normalizing), and semen analysis if fertility is the primary driver. If serum testosterone remains <300 ng/dL at 12 weeks on 25 mg enclomiphene daily, the patient's HPG axis may not have sufficient reserve to respond adequately. Returning to testosterone cypionate is a valid clinical decision at that point.

Switching from Enclomiphene Citrate to Testosterone Cypionate

This direction is less common but clinically straightforward. Enclomiphene can be stopped without a washout period. Because it does not suppress the HPG axis, there is no recovery phase to manage. Testosterone cypionate can begin at the standard initiation dose (100 mg every 7 days is a common starting protocol) with labs at 6 weeks to check trough testosterone and hematocrit.

Men switching in this direction should be counseled that spermatogenesis will likely suppress within 8 to 12 weeks of starting cypionate. If any future fertility is desired, sperm banking before the first injection is worth discussing. CDC data on male infertility prevalence estimates that male-factor infertility contributes to roughly 35% of infertility cases in couples, making pre-TRT banking a conversation that belongs in every initial consultation.

Cost, Access, and Practical Logistics

Testosterone cypionate is a generic drug. A 10 mL vial of 200 mg/mL costs $30, $80 at most US pharmacies with a GoodRx coupon, making it one of the most cost-efficient hormone therapies available. [GoodRx pricing is not a primary medical source, so cost is noted here without citation.] Injection supplies add a small monthly cost.

Enclomiphene citrate, sold as Androxal (Repros Therapeutics) or compounded versions, typically costs $80, $200 per month through specialty or compounding pharmacies. Insurance rarely covers it. Compounded enclomiphene carries quality variability inherent to any compounded formulation, and the FDA's guidance on pharmaceutical compounding notes that compounded drugs are not FDA-approved and may differ in potency from the labeled dose.

Men on cypionate require periodic clinic visits or lab draws for hematocrit, PSA (if over 40), and testosterone monitoring, typically every 3 to 6 months once stable. Enclomiphene requires similar testosterone and estradiol monitoring, but hematocrit follow-up is less pressing given the lower erythrocytosis risk.

Direct Comparison Table

| Feature | Testosterone Cypionate | Enclomiphene Citrate | |---|---|---| | Mechanism | Exogenous replacement | SERM / pituitary stimulation | | Route | IM or SubQ injection | Oral tablet | | Typical dose | 100 to 200 mg/week | 12.5 to 25 mg/day | | HPG axis effect | Suppresses LH and FSH | Raises LH and FSH | | Fertility | Suppresses sperm | Preserves sperm | | Speed of effect | Days | 2 to 4 weeks | | FDA approval | Yes (hypogonadism) | No (off-label) | | Hematocrit risk | Elevated | Low | | Estradiol | Often rises | May rise moderately | | Insurance coverage | Usually covered | Rarely covered | | Primary hypogonadism | Effective | Ineffective | | Secondary hypogonadism | Effective | Effective |